Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by...
-
66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85:...
-
AtaiBeckley today announced its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 2
-
AtaiBeckley announced the peer-reviewed publication of results from its ongoing four-part Phase 2a study of BPL-003 in the Journal of Psychopharmacology.
-
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts...
-
Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for...
-
AtaiBeckley announced participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
-
Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and long-lasting antidepressant effect for up to three months after dosing.BPL-003 was...